 |
PDBsum entry 3bjc
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of the pde5a catalytic domain in complex with a novel inhibitor
|
|
Structure:
|
 |
Cgmp-specific 3',5'-cyclic phosphodiesterase. Chain: a. Synonym: cgb-pde, cgmp-binding cgmp-specific phosphodiesterase. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: pde5a, pde5. Expressed in: escherichia coli bl21. Expression_system_taxid: 511693.
|
|
Resolution:
|
 |
|
2.00Å
|
R-factor:
|
0.197
|
R-free:
|
0.221
|
|
|
Authors:
|
 |
G.Chen,H.Wang,R.Howard,J.Cai,Y.Wan,H.Ke
|
|
Key ref:
|
 |
G.Chen
et al.
(2008).
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
Biochem Pharmacol,
75,
1717-1728.
PubMed id:
|
 |
|
Date:
|
 |
|
03-Dec-07
|
Release date:
|
29-Apr-08
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
O76074
(PDE5A_HUMAN) -
cGMP-specific 3',5'-cyclic phosphodiesterase from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
875 a.a.
311 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.1.4.35
- 3',5'-cyclic-GMP phosphodiesterase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
3',5'-cyclic GMP + H2O = GMP + H+
|
 |
 |
 |
 |
 |
3',5'-cyclic GMP
|
+
|
H2O
|
=
|
GMP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
Biochem Pharmacol
75:1717-1728
(2008)
|
|
PubMed id:
|
|
|
|
|
| |
|
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
|
|
G.Chen,
H.Wang,
H.Robinson,
J.Cai,
Y.Wan,
H.Ke.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Selective inhibitors of cyclic nucleotide phosphodiesterase-5 (PDE5) have been
used as drugs for treatment of male erectile dysfunction and pulmonary
hypertension. An insight into the pharmacophores of PDE5 inhibitors is essential
for development of second generation of PDE5 inhibitors, but has not been
completely illustrated. Here we report the synthesis of a new class of the
sildenafil derivatives and a crystal structure of the PDE5 catalytic domain in
complex with
5-(2-ethoxy-5-(sulfamoyl)-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
(12). Inhibitor 12 induces conformational change of the H-loop (residues
660-683), which is different from any of the known PDE5 structures. The
pyrazolopyrimidinone groups of 12 and sildenafil are well superimposed, but
their sulfonamide groups show a positional difference of as much as 1.5A. The
structure-activity analysis suggests that a small hydrophobic pocket and the
H-loop of PDE5 are important for the inhibitor affinity, in addition to two
common elements for binding of almost all the PDE inhibitors: the stack against
the phenylalanine and the hydrogen bond with the invariant glutamine. However,
the PDE5-12 structure does not provide a full explanation to affinity changes of
the inhibitors. Thus alternatives such as conformational change of the M-loop
are open and further structural study is required.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.L.Williams,
S.R.Dandepally,
and
S.V.Kotturi
(2010).
A p-methoxybenzyl (PMB) protection/deprotection approach toward the synthesis of 5-phenoxy-4-chloro-N-(aryl/alkyl) thiophene-2-sulfonamides.
|
| |
Mol Divers,
14,
697-707.
|
 |
|
|
|
|
 |
C.Roegler,
and
J.Lehmann
(2010).
[Medicinal chemistry of nitrates and PDE5 inhibitors].
|
| |
Pharm Unserer Zeit,
39,
351-358.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |